In 2014 BRAIN AG made a strategic investment into WeissBioTech to gain access to the growing and profitable enzyme market. Since then, BRAIN AG and WeissBioTech have worked closely together to discover, develop and sell innovative enzyme products and solutions for customers worldwide.

In 2018, BRAIN AG made another key strategic move through its acquisition of Biocatalysts Ltd. in Cardiff, UK, an enzyme company with strong fermentation technology and enzyme R&D, serving specialty niche markets. Together with BRAIN's extensive enzyme technology skills, the WeissBioTech and Biocatalysts capabilities will form a solid platform for strong growth in the specialty enzymes business.

Adriaan Moelker, CEO BRAIN AG, states: "We are continuously working to build and optimize the group structure as announced during our capital increase in June, 2020. The full acquisition and integration of WeissBioTech GmbH gives us important flexibility to optimize our production network and capture synergies within the group. I would particularly like to thank founder Hans de Bie for his significant contribution to the development of the company ( and Lukas Linnig at BRAIN who made this agreement come to fruition. Ultimately, all our stakeholders will benefit from this transaction."

 

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars. The BioScience segment comprises mainly of the research and development business with industrial partners (the "Tailor-Made Solutions" cooperation business), and the company's own research and development. The BioIndustrial segment consists mainly of the industrially scalable products business. Further information is available at .